Retroperitoneal masses encompass a variety of
entities, ranging from neural tumors like schwannomas and neurofibromas, to
fatty tissue lesions such as lipomas and liposarcomas, along with desmoids,
lymphomas, and vascular tumors like hemangiopericytomas and angiosarcomas [4].
Neurofibromas, which are rare ectodermal tumors, exceptionally involve the
retroperitoneum. They may appear as solitary growths or, more commonly, as
multiple lesions associated with conditions like neurofibromatosis type 1 (NF1)
or Von Recklinghausen's disease, which is the case with our patient [5]. These
tumors tend to grow slowly, extending into the retroperitoneum, presacral
space, and soft tissues. In most cases, they do not degenerate, except in 4 to
11% of instances linked to NF1 [2]. Our case is unique due to its rare
presacral localization [6]. These tumors often manifest at a young age [1] and
remain largely asymptomatic for an extended duration until reaching
considerable sizes [7]. This growth can lead to symptoms such as a sensation of
heaviness, digestive issues, and urinary symptoms, including hematuria,
dysuria, pollakiuria, and even renal colic. Additionally, these masses can be
complicated by a massive retroperitoneal hematoma. Preoperative imaging is
essential to establish the diagnosis. During ultrasound examination,
neurofibromas appear as well-defined masses, hypoechoic and homogeneous, with
posterior enhancement [8]. Computed tomography (CT) assesses the tumor's
extension to adjacent structures, particularly the sacral plexus, but may not
always differentiate between giant neurofibromas and neurofibrosarcomas.
Magnetic resonance imaging (MRI) stands out as the most effective modality,
providing precise details about the tumor's location and its relationships with
neighboring structures. In T1-weighted images, its intensity is slightly higher
than that of muscle, appearing hyperintense in T2. Following gadolinium
injection, contrast enhancement is heterogeneous, with a slight central
hypointensity in T1 [9].
Performing a parietal biopsy is not recommended by
some authors, as it often yields inconclusive results and poses risks of
hemorrhage, infection, and tumor dissemination [10]. Managing these types of
tumors requires a multidisciplinary team comprising visceral, orthopedic, and
neurosurgeons [12]. The standard treatment involves a carcinological surgical
excision with negative margins, emphasizing the preservation of adjacent
vascular, nervous, visceral, and bone structures. The choice of the surgical
approach depends on the degree of intra-pelvic and intra-sacral development.
Specifically, an anterior approach is favored for tumors with a significant
presacral component, while a posterior approach is suitable for intra-sacral or
intra-dural components. Occasionally, a combined sacral and abdominal approach
may be employed, as seen in our patient's case [12]. This excision demands a
certain level of surgical expertise to avoid severe complications, including
injuries to the presacral venous plexus leading to hemorrhage, or damage to the
rectum or sacral nerves [13]. However, if the tumor invades adjacent
structures, the excision may be extended to achieve negative margins, albeit at
the cost of neurosensory deficits [11]. In histopathology, a neurofibroma may
present polymorphic cells, including Schwann cells, perineural cells, and
fibroblasts contained within a mucopolysaccharide matrix. It infiltrates
between the nerve fascicles along its trajectory, making its resection
potentially difficult and risky. Immunohistochemical analysis reveals that
neurofibroma cells exhibit weak reactivity with the S-100 protein, in contrast
to schwannomas, where proliferation exclusively consists of Schwann cells, and
positive S-100 immunostaining occurs within the endoneurium of a nerve fascicle
[11]. As for radiotherapy, it is generally discouraged for benign tumours due
to its potential oncogenic risks [12].